'Lone wolf' protein offers new pathway to cancer treatments

May 17, 2018, St. Jude Children's Research Hospital
Credit: St. Jude Children's Research Hospital

Structural biologists at St. Jude Children's Research Hospital have discovered how a key protein functions to trigger cell's suicide machinery, called apoptosis. The scientists found that the protein, called BOK, is controlled separately from the rest of the apoptosis process—offering the potential for new drugs to more selectively kill cancer cells.

Led by Tudor Moldoveanu, Ph.D., an assistant member of the St. Jude Department of Structural Biology, the research appeared online May 15 in the scientific journal Cell Reports.

Apoptosis is a mechanism by which the body rids itself of that are no longer needed or malfunctioning, such as . However, cancers mutate to survive by switching off apoptosis, so a central goal of many drug treatments is to switch apoptosis on in cancer cells.

Researchers had known that BOK was central to launching apoptosis by essentially poking holes in the membrane that encloses the cells' power plants, called mitochondria. This process unleashes cell-killing proteins that, like molecular scissors, snip apart the cell's machinery, killing it.

Researchers also knew that BOK was a "lone wolf" protein, not controlled by the rest of the molecular switches. Rather, BOK is continually produced in the cell, but also continually destroyed by a protein-shredding machine called the proteasome. Only when the proteasome is inhibited do BOK levels rise.

In this new study, Moldoveanu and his colleagues revealed key details of BOK's function.

"Previously, we had found that BOK doesn't need help to execute its role," Moldoveanu said. "But we didn't have the detailed structural information that allowed us to understand BOK's mechanism of action."

The researchers used a structural analytical technique called nuclear magnetic resonance spectroscopy to probe BOK's structure. They pinpointed a special groove in the intricately folded protein that, on its own, can alter its shape to target and attach to the mitochondrial membrane. This attachment triggers BOK's membrane-destroying action.

The scientists then narrowed BOK's ability to change shape to one helix-shaped section of the . The researchers found they could freeze BOK's shape by changing one amino acid component of the helix.

Moldoveanu said the findings pave the way for a new approach to anti-cancer drugs.

"We have detailed how BOK has evolved not to need any help from activators in the apoptotic pathway," he said. "This is exciting, because it opens the way to develop new drugs that would stabilize BOK and enable it to effectively trigger apoptosis in cancer cells."

In contrast, he said, many cancer treatments aim to inhibit the prosurvival, or anti-apoptotic proteins, such as the infamous proteins BCL-2, BCL-xL and MCL-1 that block canonical apoptosis in cancer cells. To protect themselves from destruction, cancers typically mutate to over-activate these blocking, prosurvival proteins. Remarkably, BOK is not touched by the prosurvival proteins, revealing an exciting opportunity to bypass one of the hallmarks of cancer – resistance to apoptosis.

Moldoveanu and colleagues plan to explore how BOK alters its shape to attach to the mitochondrial membrane, which could guide development of drugs to enhance BOK's ability to launch apoptosis.

"We do not understand in detail BOK's conformation when it is attached to the membrane, and that is one of the holy grails of apoptosis research," he said. "That conformation will give us invaluable knowledge about how BOK permeabilizes the membrane."

The researchers also plan to trace the biological pathway by which BOK is synthesized in the cell. This could lead to the development of drugs to enhance BOK stability and its function in .

Explore further: Detailed studies reveal how key cancer-fighting protein is held in check

Related Stories

Detailed studies reveal how key cancer-fighting protein is held in check

May 15, 2014
St. Jude Children's Research Hospital scientists have mapped the structural details of how p53 attaches to its regulatory protein, called BCL-xL, in the cell. The protein p53 is a key activator of the cell's protective machinery ...

'Rheostat' identified that helps regulate cell death versus survival decisions

March 6, 2018
St. Jude Children's Research Hospital scientists have determined how a protein's disordered region serves as a molecular rheostat to help regulate cell survival.

Newly identified mechanism of p53-induced cell death could aid cancer therapy

July 30, 2015
Researchers have identified a new mechanism that the tumor suppressor protein p53 uses to trigger cell death via apoptosis and have shown how the process could be harnessed to kill cancer cells. St. Jude Children's Research ...

Scientists uncover potential trigger to kill cancer

May 26, 2016
Melbourne researchers have discovered a new way of triggering cell death, in a finding that could lead to drugs to treat cancer and autoimmune disease.

Scientists discover potential new improved way to kill cancer cells

August 29, 2017
Scientists at the University of Glasgow have discovered a process to trigger the death of cancer cells that could be more effective than current methods.

Novel treatment causes cancer to self-destruct without affecting healthy cells

October 9, 2017
Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today's issue of Cancer ...

Recommended for you

Scientists discover chemical which can kill glioblastoma cells

August 15, 2018
Aggressive brain tumour cells taken from patients self-destructed after being exposed to a chemical in laboratory tests, researchers have shown.

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

New clues into how 'trash bag of the cell' traps and seals off waste

August 15, 2018
The mechanics behind how an important process within the cell traps material before recycling it has puzzled scientists for years. But Penn State researchers have gained new insight into how this process seals off waste, ...

RUNX proteins act as regulators in DNA repair, study finds

August 15, 2018
A study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has revealed that RUNX proteins are integral to efficient DNA repair via the Fanconi Anemia (FA) ...

Chemicals found in vegetables prevent colon cancer in mice

August 14, 2018
Chemicals produced by vegetables such as kale, cabbage and broccoli could help to maintain a healthy gut and prevent colon cancer, a new study from the Francis Crick Institute shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.